TC-6987: Completed Phase II enrollment

Targacept disclosed in its 4Q11 earnings that it completed enrollment of about 90 patients in a double-blind, placebo-controlled, U.S. Phase II trial evaluating once-daily TC-6987 for 4 weeks. Patient...